Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Decrement in Cellular Iron and Reactive Oxygen Species, and Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract.

Koonyosying P, Uthaipibull C, Fucharoen S, Koumoutsea EV, Porter JB, Srichairatanakool S.

Pancreas. 2019 May/Jun;48(5):636-643. doi: 10.1097/MPA.0000000000001320.

2.

Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.

Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31. No abstract available.

3.

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.

Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB.

Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5.

4.

Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.

Taher AT, Weber S, Han J, Bruederle A, Porter JB.

Am J Hematol. 2019 Jan;94(1):E15-E17. doi: 10.1002/ajh.25322. Epub 2018 Nov 15. No abstract available.

5.

Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia.

Vosper J, Evangeli M, Porter JB, Shah F.

Hemoglobin. 2018 Jan;42(1):30-36. doi: 10.1080/03630269.2018.1433686. Epub 2018 Mar 9.

PMID:
29521137
6.

Interaction of Transfusion and Iron Chelation in Thalassemias.

Porter JB, Garbowski MW.

Hematol Oncol Clin North Am. 2018 Apr;32(2):247-259. doi: 10.1016/j.hoc.2017.11.010. Review.

PMID:
29458730
7.

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?

Cappellini MD, Porter JB, Viprakasit V, Taher AT.

Blood Rev. 2018 Jul;32(4):300-311. doi: 10.1016/j.blre.2018.02.001. Epub 2018 Feb 12. Review.

8.

Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center.

Porter JB, Rosenthal EL, Winget M, Smith AS, Seshadri SB, Vetteth Y, Kiamanesh EF, Badwe A, Advani RH, Buyyounouski MK, Coutre S, Dirbas F, Divi V, Dorigo O, Ganjoo KN, Johnston LJ, Recht LD, Shrager JB, Skinner EC, Swetter SM, Visser BC, Blayney DW.

J Oncol Pract. 2017 Aug;13(8):e673-e682. doi: 10.1200/JOP.2017.021139. Epub 2017 Jul 20.

9.

Predictors of readmissions after head and neck cancer surgery: A national perspective.

Chen MM, Orosco RK, Harris JP, Porter JB, Rosenthal EL, Hara W, Divi V.

Oral Oncol. 2017 Aug;71:106-112. doi: 10.1016/j.oraloncology.2017.06.010.

PMID:
28688676
10.

Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.

Garbowski MW, Evans P, Vlachodimitropoulou E, Hider R, Porter JB.

Haematologica. 2017 Oct;102(10):1640-1649. doi: 10.3324/haematol.2017.170605. Epub 2017 Jun 22.

11.

Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia.

Kirk P, Sheppard M, Carpenter JP, Anderson L, He T, St Pierre T, Galanello R, Catani G, Wood J, Fucharoen S, Porter JB, Walker JM, Forni GL, Pennell DJ.

J Cardiovasc Magn Reson. 2017 Mar 27;19(1):36. doi: 10.1186/s12968-017-0349-3.

12.

Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemia.

Jackson LH, Vlachodimitropoulou E, Shangaris P, Roberts TA, Ryan TM, Campbell-Washburn AE, David AL, Porter JB, Lythgoe MF, Stuckey DJ.

Sci Rep. 2017 Feb 27;7:43439. doi: 10.1038/srep43439.

13.

New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.

Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB.

Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.

14.

Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects.

Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, Cho G, Ryan K; British Committee for Standards in Haematology.

Br J Haematol. 2017 Jan;176(2):179-191. doi: 10.1111/bjh.14346. Epub 2016 Nov 7. No abstract available.

PMID:
28092109
15.

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.

Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD.

Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016. No abstract available.

16.

Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT.

Br J Haematol. 2017 Jan;176(2):288-299. doi: 10.1111/bjh.14373. Epub 2016 Dec 5.

17.

Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.

Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A.

Eur J Haematol. 2017 Mar;98(3):280-288. doi: 10.1111/ejh.12830. Epub 2017 Jan 13.

PMID:
27859648
18.

Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion.

Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, Cho G, Ryan K; British Society for Haematology.

Br J Haematol. 2017 Jan;176(2):192-209. doi: 10.1111/bjh.14383. Epub 2016 Nov 18. No abstract available.

PMID:
27858994
19.

One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.

Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB.

Pediatr Blood Cancer. 2017 Jan;64(1):188-196. doi: 10.1002/pbc.26213. Epub 2016 Aug 31.

PMID:
27576370
20.

Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World: The TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR).

Abdel-Gadir A, Vorasettakarnkij Y, Ngamkasem H, Nordin S, Ako EA, Tumkosit M, Sucharitchan P, Uaprasert N, Kellman P, Piechnik SK, Fontana M, Fernandes JL, Manisty C, Westwood M, Porter JB, Walker JM, Moon JC.

Circulation. 2016 Aug 2;134(5):432-4. doi: 10.1161/CIRCULATIONAHA.116.022803. No abstract available.

21.

Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay.

Garbowski MW, Ma Y, Fucharoen S, Srichairatanakool S, Hider R, Porter JB.

Transl Res. 2016 Nov;177:19-30.e5. doi: 10.1016/j.trsl.2016.05.005. Epub 2016 Jun 7.

22.

Red blood cell-derived microparticles: An overview.

Westerman M, Porter JB.

Blood Cells Mol Dis. 2016 Jul;59:134-9. doi: 10.1016/j.bcmd.2016.04.003. Epub 2016 Apr 13. Review.

PMID:
27282583
23.

Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance.

Abdel-Gadir A, Berber R, Porter JB, Quinn PD, Suri D, Kellman P, Hart AJ, Moon JC, Manisty C, Skinner JA.

J Cardiovasc Magn Reson. 2016 May 6;18(1):29. doi: 10.1186/s12968-016-0248-z.

24.

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.

Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Wang C, Zhu Z, Joaquin V, Uwamahoro MJ, Lai YR.

Blood Cells Mol Dis. 2016 Mar;57:23-9. doi: 10.1016/j.bcmd.2015.11.002. Epub 2015 Nov 11.

25.

Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update.

Oliveira A, Warcel D, Huntley N, Eleftheriou P, Porter JB.

Hemoglobin. 2016;40(2):127-9. doi: 10.3109/03630269.2015.1136935. Epub 2016 Feb 6.

PMID:
26852627
26.

New insights into transfusion-related iron toxicity: Implications for the oncologist.

Porter JB, de Witte T, Cappellini MD, Gattermann N.

Crit Rev Oncol Hematol. 2016 Mar;99:261-71. doi: 10.1016/j.critrevonc.2015.11.017. Epub 2015 Nov 27. Review.

PMID:
26806144
27.

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

Cappellini MD, Porter JB, Musallam KM, Kattamis A, Viprakasit V, Galanello R, Taher AT.

Eur J Intern Med. 2016 Mar;28:91-6. doi: 10.1016/j.ejim.2015.10.003.

PMID:
26545830
28.

The effects of age and physical health on processing speed in HIV.

Van Dyk K, Golub SA, Porter JB, Robin KJ, Kowalczyk WJ, Tomassilli JC, Ly JJ, Foldi NS.

AIDS Care. 2015;27(10):1326-31. doi: 10.1080/09540121.2015.1054340.

PMID:
26468908
29.

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.

Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, Winer EP, Hammond SP, Baden LR.

Breast Cancer Res Treat. 2015 Nov;154(2):359-67. doi: 10.1007/s10549-015-3573-2. Epub 2015 Sep 29.

PMID:
26420402
30.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW.

Haematologica. 2016 Jan;101(1):38-45. doi: 10.3324/haematol.2015.133983. Epub 2015 Sep 18.

31.

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.

Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilinç Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB; HYPERION Investigators.

Blood. 2015 Jun 18;125(25):3868-77. doi: 10.1182/blood-2014-07-586677. Epub 2015 May 1.

32.

Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA; Thalassemia Clinical Research Network.

Br J Haematol. 2015 Jun;169(6):887-98. doi: 10.1111/bjh.13452. Epub 2015 Apr 24.

33.

Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.

Porter JB, El-Alfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, El-Ali A, Han J, Cappellini MD.

Eur J Haematol. 2016 Jan;96(1):19-26. doi: 10.1111/ejh.12540. Epub 2015 Jun 23.

PMID:
25691036
34.

Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.

Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, Wray K, Premawardhena A, Bandara D, Perera A, Webster C, Sturges P, Olivieri NF, St Pierre T, Armitage AE, Porter JB, Weatherall DJ, Drakesmith H.

Blood. 2015 Jan 29;125(5):873-80. doi: 10.1182/blood-2014-10-606491. Epub 2014 Dec 17.

35.

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.

Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ.

Eur J Haematol. 2015 Sep;95(3):244-53. doi: 10.1111/ejh.12487. Epub 2015 Jan 8.

36.

Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.

Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, Yesilipek A, Kilinç Y, Habr D, Musallam KM, Shen J, Aydinok Y; CORDELIA study investigators.

Am J Hematol. 2015 Feb;90(2):91-6. doi: 10.1002/ajh.23876. Epub 2014 Nov 19.

37.

Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice.

Chansiw N, Pangjit K, Phisalaphong C, Porter JB, Evans P, Fucharoen S, Srichairatanakool S.

Asian Pac J Trop Med. 2014 Sep;7S1:S155-61. doi: 10.1016/S1995-7645(14)60223-6.

38.

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.

Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12.

PMID:
25212456
39.

Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.

Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, Weyhmiller MG, Harmatz PR, Wood JC, Miller JL, Byrnes C, Weiss G, Seifert M, Grosse R, Grabowski D, Schmidt A, Fischer R, Nielsen P, Niemeyer C, Vichinsky E.

Br J Haematol. 2014 Dec;167(5):692-6. doi: 10.1111/bjh.13081. Epub 2014 Sep 11.

40.

Calibration of myocardial T2 and T1 against iron concentration.

Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Baksi AJ, Sheppard MN, Porter JB, Walker JM, Wood JC, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House M, Black G, Firmin DN, St Pierre TG, Pennell DJ.

J Cardiovasc Magn Reson. 2014 Aug 12;16:62. doi: 10.1186/s12968-014-0062-4.

41.

The pathophysiology of transfusional iron overload.

Porter JB, Garbowski M.

Hematol Oncol Clin North Am. 2014 Aug;28(4):683-701, vi. doi: 10.1016/j.hoc.2014.04.003. Review.

PMID:
25064708
42.

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.

Garbowski MW, Carpenter JP, Smith G, Roughton M, Alam MH, He T, Pennell DJ, Porter JB.

J Cardiovasc Magn Reson. 2014 Jun 10;16:40. doi: 10.1186/1532-429X-16-40.

43.

High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major.

Chatterjee R, Bajoria R, Shah FT, Porter JB, Fedele S.

Br J Haematol. 2014 Jul;166(2):292-4. doi: 10.1111/bjh.12833. Epub 2014 Mar 14. No abstract available.

PMID:
24628574
44.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.

Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25.

45.

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators.

Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2.

46.

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.

Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):88-90. doi: 10.1016/j.bcmd.2013.08.006. Epub 2013 Sep 13. No abstract available.

PMID:
24041597
47.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD.

Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18.

48.

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.

Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging.

Circulation. 2013 Jul 16;128(3):281-308. doi: 10.1161/CIR.0b013e31829b2be6. Epub 2013 Jun 17. Erratum in: Circulation. 2013 Sep 24;128(13):e203.

PMID:
23775258
49.

Raised haematocrit concentration and the risk of death and vascular complications after major surgery.

Musallam KM, Porter JB, Sfeir PM, Tamim HM, Richards T, Lotta LA, Peyvandi F, Jamali FR.

Br J Surg. 2013 Jul;100(8):1030-6. doi: 10.1002/bjs.9176.

PMID:
23754644
50.

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.

Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F.

J Cardiovasc Magn Reson. 2013 May 20;15:38. doi: 10.1186/1532-429X-15-38.

Supplemental Content

Loading ...
Support Center